ClinicalTrials.gg
RecruitingNCT06478693Updated Dec 18, 2025

A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC

A Phase 1 interventional study of MT-303 and MT-303 +Atezolizumab + Bevacizumab in Hepatocellular Carcinoma, sponsored by Myeloid Therapeutics. Recruiting at 9 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by Myeloid Therapeutics · Phase 1, Interventional, and Treatment

How we know · 10 judgments

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies testing atezolizumab in Carcinoma, Hepatocellular — 17 open to participants now, 29 under way, 7 of them phase 3. atezolizumab · Carcinoma, Hepatocellular.

Planned enrollment
17th of 41
70 · median 40
Started
2024
with 1 other
Phase 1
3 of 41
1 open now
Primary completion
2027-12
later than 20 of 28 live
Registered
33rd of 41
by date

Among the 41 studies testing atezolizumab in Carcinoma, Hepatocellular, this one is the 17th largest by planned enrollment, is one of 2 that started in 2024, is one of 3 in phase 1, reaches primary completion later than 20 of the 28 other live ones, and was the 33rd registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

17 of the 41 studies testing atezolizumab in Carcinoma, Hepatocellular are open now, in 11 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About atezolizumab

atezolizumab: first FDA approval 2016 (TECENTRIQ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing atezolizumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

This is a multicenter, open-label, Phase 1, first-in-human, dose-escalation study designed to assess the safety, tolerability and define the RP2D of MT-303 alone (Module 1) and in combination with Atezo/Bev (Module 2) in participants with advanced hepatocellular carcinoma expressing GPC3.

Read the detailed description

Participants will be enrolled into one of two treatment modules:

  • Module 1 (Monotherapy): Participants will receive MT-303.
  • Module 2 (Combination therapy): Participants will receive MT-303 in combination with atezolizumab + bevacizumab (Atezo/Bev).

In Module 1 (Monotherapy), participants will receive MT-303 across five dose-escalation cohorts and in Module 2 (Combination therapy), participants will receive MT-303 in combination with Atezo/Bev across five dose-escalation cohorts.

Additional cohorts in both modules may be scheduled based on emerging safety and PK data.

Participants will be sequentially enrolled into Cohorts 1 through 5. Both modules will be enrolled concurrently, with Module 2 dosing beginning at one dose level below the known safe dose in Module 1. Safety Review Committee decisions will be informed by all available safety data from Modules 1 and 2.

03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • Liver Cancer
  • Hepatocellular Carcinoma (HCC)
  • Glypican-3
  • Chimeric antigen receptor
  • CAR-M
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria

  • Aged 18 years or older
  • Histological diagnosis of advanced/recurrent or and/or unresectable HCC. [Note: participants with other tumor types expressing GPC3 may be eligible for Module 1 pending a discussion with the Medical Monitor. Only participants with HCC are eligible for Module 2.
  • per 1.1 criteria
  • (ECOG) performance status grade of 0 or 1
  • score: Class A
  • Adequate organ function

General Exclusion Criteria

  • Known active and/or carcinomatous meningitis.
  • Any acute illness including active infection
  • History of liver transplantation or on waiting list
  • Participants with untreated or incompletely treated varices with bleeding or high risk for bleeding
  • Uncontrolled pleural effusion, pericardial effusion, or ascites
  • History of symptomatic congestive heart failure
  • History of chronic or recurrent (within the last year) severe or immune mediated disease requiring or other immune-suppressive treatments.

Additional Module 2 Exclusion Criteria:

  • Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.
  • Significant cardiovascular disease
  • History of severe to atezolizumab and/or bevacizumab.
  • History of idiopathic pulmonary fibrosis
  • Prior history of hypertensive crisis or hypertensive encephalopathy.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    MT-303

    Participants will receive MT-303 through intravenous infusion.

    Drug: MT-303

  • Experimental
    MT-303 + Atezolizumab + Bevacizumab

    Participants will receive MT-303 in combination with Atezo/Bev through intravenous infusion.

    Drug: MT-303 +Atezolizumab + Bevacizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Type, incidence and severity of Adverse Events

    Safety and tolerability profile assessed by the Common Terminology Criteria for Adverse Events v5.0

    Time frame: Up to 2 years from the last dose of Investigational Medicinal Product (IMP)

  2. Recommended Phase 2 Dose (RP2D)

    The RP2D will be determined using dose limiting toxicities (DLTs) and all other available study data

    Time frame: 28 days from the last dose of IMP

  3. Optimal Biological dose (OBD)

    The OBD will be determined using dose limiting toxicities (DLTs) and all other available study data

    Time frame: 21 days from the last dose of IMP

  4. Change from baseline in vital signs

    Temperature, weight, height, pulse rate and blood pressure will be assessed

    Time frame: Up to 30 days from the last dose of IMP

  5. Change in laboratory parameters

    Hematology, chemistry, coagulation, virology and urine analysis will be assessed.

    Time frame: Up to 30 days from the last dose of IMP

  6. Change from baseline in ECG parameters

    Time frame: Screening, Day 1 and Day 15

Secondary outcomes

  1. Pharmacokinetics (PK)

    PK parameter: Plasma concentrations

    Time frame: Day 1, 2, 3, 8, 15 and once every 28 days post first dose of IMP for Module 1 and Day 1, 2, 8 and once every 21 days post first dose of IMP for Module 2.

  2. Pharmacokinetics (PK)

    PK parameter: Area under Curve

    Time frame: Day 1, 2, 3, 8, 15 and once every 28 days post first dose of IMP for Module 1 and Day 1, 2, 8 and once every 21 days post first dose of IMP for Module 2.

  3. Pharmacokinetics (PK)

    PK parameter: Time of maximum observed plasma concentration (tmax)

    Time frame: Day 1, 2, 3, 8, 15 and once every 28 days post first dose of IMP for Module 1 and Day 1, 2, 8 and once every 21 days post first dose of IMP for Module 2.

  4. Pharmacokinetics (PK)

    PK parameter: Plasma Clearance (CL)

    Time frame: Day 1, 2, 3, 8, 15 and once every 28 days post first dose of IMP for Module 1 and Day 1, 2, 8 and once every 21 days post first dose of IMP for Module 2.

  5. Pharmacokinetics (PK)

    PK parameter: Volume of Distribution (Vd)

    Time frame: Day 1, 2, 3, 8, 15 and once every 28 days post first dose of IMP for Module 1 and Day 1, 2, 8 and once every 21 days post first dose of IMP for Module 2.

  6. Pharmacokinetics (PK)

    PK parameter: Mean residence time (MRT)

    Time frame: Day 1, 2, 3, 8, 15 and once every 28 days post first dose of IMP for Module 1 and Day 1, 2, 8 and once every 21 days post first dose of IMP for Module 2.

  7. Pharmacokinetics (PK)

    PK parameter: terminal rate constant (λz)

    Time frame: Day 1, 2, 3, 8, 15 and once every 28 days post first dose of IMP for Module 1 and Day 1, 2, 8 and once every 21 days post first dose of IMP for Module 2.

  8. To assess adverse events of special interest (AESI) by measuring infusion reaction

    Time frame: upto 2 years from the last dose of IMP

  9. To assess adverse events of special interest (AESI) by measuring cytokine release syndrome (CRS)

    Time frame: Up to 2 years from the last dose of IMP

  10. To assess adverse events of special interest (AESI) by measuring immune effector cell-associated neurotoxicity syndrome (ICANS)

    Time frame: Up to 2 years from the last dose of IMP

  11. To assess adverse events of special interest (AESI) by measuring hypersensitivity reaction

    Time frame: Up to 2 years from the last dose of IMP

  12. To assess adverse events of special interest (AESI) by checking for second primary malignancy

    Time frame: upto 2 years from the last dose of IMP

07

Study locations

9 of 9 sites recruiting
  • St Vincent's Hospital
    Sydney, New South Wales 2010, Australia
    Recruiting
    • Hao-Wen Sim, MD · Contact
  • Integrated Clinical Oncology Network (ICON) Pty Ltd
    Woolloongabba, Queensland 4102, Australia
    Recruiting
    • Vladimir Andelkovic, MD · Contact
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
    Recruiting
    • Stuart Roberts, MD · Contact
  • Linear Clinical Research
    Murdoch, Western Australia 6150, Australia
    Recruiting
    • Tim Humphries, MD · Contact
  • Pusan National Univesity Hospital
    Busan, South Korea
    Recruiting
    • Jeong Heo, MD · Contact
  • Cha University Bundang Medical Center
    Gyeonggi-do, South Korea
    Recruiting
    • Hongjae Jeoon, MD · Contact
  • Seoul National University Hospital
    Seoul, South Korea
    Recruiting
    • Yoon Jun Kim, MD · Contact
  • National Taiwan University Hospital
    Taipei, Taiwan
    Recruiting
    • Chih-hung Hsu · Contact
  • Taipei Tzu Chi Hospital
    Taipei, Taiwan
    Recruiting
    • Her-shyong Shiah · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Dec 2027, 41 months after the start.

Of 103 industry-sponsored phase 1 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 41 months is below that.

Counting every sponsor, half of 250 studies reached it within 49 months; a quarter within 32 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2024
First posted
Jun 27, 2024
StartActual
Jul 1, 2024
Primary completionEst.
Dec 31, 2027
CompletionEst.
May 31, 2028
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06478693
Lead sponsor
Myeloid Therapeutics
Collaborators
CREATE Medicines
Responsible party
Sponsor
First posted
Jun 27, 2024
Start date
Jul 1, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Dec 18, 2025

Study contacts

Project Manager
Contact
Lucy.FrereScott@novotech-cro.com
+61 2 8569 1400
Clinical Department
Contact
303clinical@myeloidtx.com
+1 617 465 1022
Matthew Maurer, MD
study director · Myeloid Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atezolizumab · Bevacizumab

Start the discussion